Amy Hauck Newman

From WikiMD's Food, Medicine & Wellness Encyclopedia

Amy Hauck Newman is an American neuroscientist and pharmacologist known for her extensive research in the field of drug addiction. She is currently serving as the Scientific Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH).

Early Life and Education[edit | edit source]

Newman was born and raised in the United States. She pursued her undergraduate studies in chemistry and biology before moving on to earn her Ph.D. in pharmacology.

Career[edit | edit source]

Newman's career has been marked by her significant contributions to the field of neuroscience and pharmacology. She has been involved in the development of novel radioligands for imaging studies related to drug addiction. Her work has significantly advanced our understanding of the neurobiological mechanisms underlying drug addiction.

At the National Institutes of Health, Newman leads a team of researchers dedicated to studying the effects of drugs on the brain. Her research has been instrumental in the development of new treatments for drug addiction.

Research[edit | edit source]

Newman's research focuses on the development of novel radioligands for Positron Emission Tomography (PET) imaging studies. These radioligands are used to visualize and study the brain's response to drugs of abuse. Her work has led to a better understanding of the neurobiological mechanisms underlying drug addiction.

Awards and Recognition[edit | edit source]

Throughout her career, Newman has received numerous awards and recognition for her contributions to the field of neuroscience and pharmacology. She is a respected figure in her field and her work continues to influence the direction of research in drug addiction.

See Also[edit | edit source]


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD